Skip to main content

November 2015

 

 

academics

 

Clinical research courses

Opportunity for Executive- Domestic Marketing - Aspiring-Solutions

Our client co. was established in the year 1983, with their main manufacturing facility at MIDC Taloja in Maharashtra, we one of the leading Industrial Chemical Products Manufacturer among Chemicals Industries, are engaged in manufacturing specialty solvents like 1,4-Dioxane, 1,3-Dioxolane, Methylal, Monoglyme, Diglyme, Potassium Hydrogen Phthalate and many more industrial chemical products that find application as water treatment chemicals and in various pharmaceutical and drug companies.

QA/QC Officer - Fireproofing Materials in Aspiring-Solutions

Our client is innovative solution driven organization offering the most modern, tested and approved world standard systems in the fields of passive fire protection, steel frame construction, protective coatings, acoustical and thermal insulation.

Post: QA/QC Officer - Fireproofing Materials

Full Time Consultant – Clinical Data Management in CDSA

Clinical Development Services Agency (CDSA) mission is to create, develop, and nurture world-class clinical product development capacity in India.

Post: Full Time Consultant – Clinical Data Management

Application are invited for Innovative Young Biotechnologist Award for the year 2015

The ‘Innovative Young Biotechnologist Award’ (IYBA) was instituted by the Department of Biotechnology in the year 2005, as an attractive, career-oriented scheme to identify and nurture outstanding young scientists with innovative ideas and desire to pursue research in frontier areas of biotechnology. For the year 2015 awards the department invites applications from the young investigators upto the age of 35 years. The award will consist of financial support for a project and Cash Award/fellowship for the awardees. Awardees having a regular employment will receive a cash award of Rs. 1.00/- Lakh every year during the course of the project in addition to grants-in-aid of Rs. 50.00/- Lakhs for a project. The awardees, those are not in the regular employment will receive a fellowship of Rs. 75,000/- per month with grants-in-aid and shall be attached to a Senior Scientist (Mentor) in a University, Research Institute, Medical/Agriculture/ Veterinary College or any other institute of repute. It is expected that the awardees will work independently and the Mentor will facilitate the awardees research efforts. Applications (2 copies) neatly typed on plain paper in the prescribed format along with enclosures & certified copies to be sent to Dr. T. Madhan Mohan, Adviser, Department of Biotechnology, Block-2, CGO Complex, Lodi Road, New Delhi – 110 003, so as to reach latest by 31st December, 2015. Soft copy of the application also needs to be sent to: iyba.dbt@nic.in. For more details and application format, please visit DBT websites: dbtindia.gov.in/iyba.htm OR btisnet.gov.in/iyba.htm

Pfizer Inc. announced that PROFILE 1029, a Phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor XALKORI® (crizotinib), met its primary objective of significantly prolonging progression-free survival (PFS) in previously untreated East Asian patients with ALK-positive advanced non-small cell lung cancer (NSCLC) when compared to a standard chemotherapy doublet. In this study, XALKORI was used as the first systemic therapy for patients with advanced ALK-positive NSCLC, and patients could have received therapy and/or surgery for early stage disease before they were diagnosed with metastatic disease.

Merck KGaA, Darmstadt, Germany, and Pfizer announced that the US Food and Drug Administration (FDA) has granted avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Breakthrough Therapy designation for the treatment of patients with metastatic Merkel cell carcinoma (MCC) who have progressed after at least one previous chemotherapy regimen. Breakthrough Therapy designation is designed to accelerate the development and review of medicines that are intended to treat a serious condition, and preliminary clinical evidence indicates that the therapy may demonstrate a substantial improvement over current available therapies.

Medtronic plc announced US Food and Drug Administration (FDA) approval and US commercial availability of the MyCareLink Smart Monitor, the world's first app-based remote monitoring system for patients with implantable pacemakers. With the MyCareLink Smart Monitor, patients with a Medtronic pacemaker can use their own smartphone or tablet technology, with cellular or Wi-Fi service, to securely transmit data from their pacemakers to their physicians, who can then interpret the data to make treatment decisions.

U.S. Food and Drug Administration approved Narcan nasal spray, the first FDA-approved nasal spray version of naloxone hydrochloride, a life-saving medication that can stop or reverse the effects of an opioid overdose. Opioids are a class of drugs that include prescription medications such as oxycodone, hydrocodone, and morphine, as well as the illegal drug heroin.

US ambassador to India Richard R. Verma on Friday said India is worst effected by tuberculosis (TB) and needs more efforts to fight the disease. Verma said TB was grabbing and finishing India. He said every year 2.2 million people were becoming victim of TB.